Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
This artificial RNA ligase has higher thermostability than natural RNA ligase
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The new sterile filling line meets cGMP aseptic filling regulatory requirements
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Subscribe To Our Newsletter & Stay Updated